カテゴリー： Market Monitor Global, 世界, 医療/バイオ

進行性運動失調無力症治療の世界市場見通し2023年-2029年

◆英語タイトル：Syndrome Progressive Ataxia Weakness Disorder Treatment Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが発行した調査報告書（MMG23FB2420）

◆商品コード：MMG23FB2420
◆発行会社（リサーチ会社）：Market Monitor Global
◆発行日：2023年2月
◆ページ数：68
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後2-3営業日）
◆調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
◆産業分野：医療機器

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,250 ⇒換算￥494,000	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD4,225 ⇒換算￥642,200	見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）	USD4,875 ⇒換算￥741,000	見積依頼/購入/質問フォーム

★Market Monitor Globalに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

当調査レポートは次の情報を含め、世界の進行性運動失調無力症治療市場規模と予測を収録しています。・世界の進行性運動失調無力症治療市場：売上、2018年-2023年、2024年-2029年
・世界の進行性運動失調無力症治療市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の進行性運動失調無力症治療市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「タンパク質ミスフォールディング」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

進行性運動失調無力症治療のグローバル主要企業は、Acorda Therapeutics、American Regent、Baxter International、Biogen Idec、Bristol-Myers Squibb、Cadila Healthcare、Eli Lilly and Company、Glaxosmilthkline、Sanofi、Roche Holding、Pfizer、Novartis AGなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、進行性運動失調無力症治療のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界の進行性運動失調無力症治療市場：タイプ別、2018年-2023年、2024年-2029年
世界の進行性運動失調無力症治療市場：タイプ別市場シェア、2022年
・タンパク質ミスフォールディング、幹細胞治療

世界の進行性運動失調無力症治療市場：用途別、2018年-2023年、2024年-2029年
世界の進行性運動失調無力症治療市場：用途別市場シェア、2022年
・医療検査室、治療センター、その他

世界の進行性運動失調無力症治療市場：地域・国別、2018年-2023年、2024年-2029年
世界の進行性運動失調無力症治療市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業における進行性運動失調無力症治療のグローバル売上、2018年-2023年
・主要企業における進行性運動失調無力症治療のグローバル売上シェア、2022年
・主要企業における進行性運動失調無力症治療のグローバル販売量、2018年-2023年
・主要企業における進行性運動失調無力症治療のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
Acorda Therapeutics、American Regent、Baxter International、Biogen Idec、Bristol-Myers Squibb、Cadila Healthcare、Eli Lilly and Company、Glaxosmilthkline、Sanofi、Roche Holding、Pfizer、Novartis AG

*************************************************************

・調査・分析レポートの概要
進行性運動失調無力症治療市場の定義
市場セグメント
世界の進行性運動失調無力症治療市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の進行性運動失調無力症治療市場規模
世界の進行性運動失調無力症治療市場規模：2022年 VS 2029年
世界の進行性運動失調無力症治療市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの進行性運動失調無力症治療の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の進行性運動失調無力症治療製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：タンパク質ミスフォールディング、幹細胞治療
進行性運動失調無力症治療のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：医療検査室、治療センター、その他
進行性運動失調無力症治療の用途別グローバル売上・予測

・地域別市場分析
地域別進行性運動失調無力症治療市場規模 2022年と2029年
地域別進行性運動失調無力症治療売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
Acorda Therapeutics、American Regent、Baxter International、Biogen Idec、Bristol-Myers Squibb、Cadila Healthcare、Eli Lilly and Company、Glaxosmilthkline、Sanofi、Roche Holding、Pfizer、Novartis AG
...

This report aims to provide a comprehensive presentation of the global market for Syndrome Progressive Ataxia Weakness Disorder Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Syndrome Progressive Ataxia Weakness Disorder Treatment. This report contains market size and forecasts of Syndrome Progressive Ataxia Weakness Disorder Treatment in global, including the following market information:
Global Syndrome Progressive Ataxia Weakness Disorder Treatment Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Syndrome Progressive Ataxia Weakness Disorder Treatment market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Protein Misfolding Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Syndrome Progressive Ataxia Weakness Disorder Treatment include Acorda Therapeutics, American Regent, Baxter International, Biogen Idec, Bristol-Myers Squibb, Cadila Healthcare, Eli Lilly and Company, Glaxosmilthkline and Sanofi, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Syndrome Progressive Ataxia Weakness Disorder Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
[Total Market by Segment]
Global Syndrome Progressive Ataxia Weakness Disorder Treatment Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Syndrome Progressive Ataxia Weakness Disorder Treatment Market Segment Percentages, by Type, 2022 (%)
Protein Misfolding
Stem Cell Therapies
Global Syndrome Progressive Ataxia Weakness Disorder Treatment Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Syndrome Progressive Ataxia Weakness Disorder Treatment Market Segment Percentages, by Application, 2022 (%)
Medical Laboratory
Treatment Center
Others
Global Syndrome Progressive Ataxia Weakness Disorder Treatment Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Syndrome Progressive Ataxia Weakness Disorder Treatment Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Syndrome Progressive Ataxia Weakness Disorder Treatment revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Syndrome Progressive Ataxia Weakness Disorder Treatment revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Acorda Therapeutics
American Regent
Baxter International
Biogen Idec
Bristol-Myers Squibb
Cadila Healthcare
Eli Lilly and Company
Glaxosmilthkline
Sanofi
Roche Holding
Pfizer
Novartis AG
Outline of Major Chapters:
Chapter 1: Introduces the definition of Syndrome Progressive Ataxia Weakness Disorder Treatment, market overview.
Chapter 2: Global Syndrome Progressive Ataxia Weakness Disorder Treatment market size in revenue.
Chapter 3: Detailed analysis of Syndrome Progressive Ataxia Weakness Disorder Treatment company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Syndrome Progressive Ataxia Weakness Disorder Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Syndrome Progressive Ataxia Weakness Disorder Treatment Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Syndrome Progressive Ataxia Weakness Disorder Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Syndrome Progressive Ataxia Weakness Disorder Treatment Overall Market Size
2.1 Global Syndrome Progressive Ataxia Weakness Disorder Treatment Market Size: 2022 VS 2029
2.2 Global Syndrome Progressive Ataxia Weakness Disorder Treatment Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Syndrome Progressive Ataxia Weakness Disorder Treatment Players in Global Market
3.2 Top Global Syndrome Progressive Ataxia Weakness Disorder Treatment Companies Ranked by Revenue
3.3 Global Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue by Companies
3.4 Top 3 and Top 5 Syndrome Progressive Ataxia Weakness Disorder Treatment Companies in Global Market, by Revenue in 2022
3.5 Global Companies Syndrome Progressive Ataxia Weakness Disorder Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Syndrome Progressive Ataxia Weakness Disorder Treatment Players in Global Market
3.6.1 List of Global Tier 1 Syndrome Progressive Ataxia Weakness Disorder Treatment Companies
3.6.2 List of Global Tier 2 and Tier 3 Syndrome Progressive Ataxia Weakness Disorder Treatment Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Syndrome Progressive Ataxia Weakness Disorder Treatment Market Size Markets, 2022 & 2029
4.1.2 Protein Misfolding
4.1.3 Stem Cell Therapies
4.2 By Type – Global Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue & Forecasts
4.2.1 By Type – Global Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, 2018-2023
4.2.2 By Type – Global Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, 2024-2029
4.2.3 By Type – Global Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Syndrome Progressive Ataxia Weakness Disorder Treatment Market Size, 2022 & 2029
5.1.2 Medical Laboratory
5.1.3 Treatment Center
5.1.4 Others
5.2 By Application – Global Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue & Forecasts
5.2.1 By Application – Global Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, 2018-2023
5.2.2 By Application – Global Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, 2024-2029
5.2.3 By Application – Global Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Syndrome Progressive Ataxia Weakness Disorder Treatment Market Size, 2022 & 2029
6.2 By Region – Global Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue & Forecasts
6.2.1 By Region – Global Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, 2018-2023
6.2.2 By Region – Global Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, 2024-2029
6.2.3 By Region – Global Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, 2018-2029
6.3.2 US Syndrome Progressive Ataxia Weakness Disorder Treatment Market Size, 2018-2029
6.3.3 Canada Syndrome Progressive Ataxia Weakness Disorder Treatment Market Size, 2018-2029
6.3.4 Mexico Syndrome Progressive Ataxia Weakness Disorder Treatment Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, 2018-2029
6.4.2 Germany Syndrome Progressive Ataxia Weakness Disorder Treatment Market Size, 2018-2029
6.4.3 France Syndrome Progressive Ataxia Weakness Disorder Treatment Market Size, 2018-2029
6.4.4 U.K. Syndrome Progressive Ataxia Weakness Disorder Treatment Market Size, 2018-2029
6.4.5 Italy Syndrome Progressive Ataxia Weakness Disorder Treatment Market Size, 2018-2029
6.4.6 Russia Syndrome Progressive Ataxia Weakness Disorder Treatment Market Size, 2018-2029
6.4.7 Nordic Countries Syndrome Progressive Ataxia Weakness Disorder Treatment Market Size, 2018-2029
6.4.8 Benelux Syndrome Progressive Ataxia Weakness Disorder Treatment Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, 2018-2029
6.5.2 China Syndrome Progressive Ataxia Weakness Disorder Treatment Market Size, 2018-2029
6.5.3 Japan Syndrome Progressive Ataxia Weakness Disorder Treatment Market Size, 2018-2029
6.5.4 South Korea Syndrome Progressive Ataxia Weakness Disorder Treatment Market Size, 2018-2029
6.5.5 Southeast Asia Syndrome Progressive Ataxia Weakness Disorder Treatment Market Size, 2018-2029
6.5.6 India Syndrome Progressive Ataxia Weakness Disorder Treatment Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, 2018-2029
6.6.2 Brazil Syndrome Progressive Ataxia Weakness Disorder Treatment Market Size, 2018-2029
6.6.3 Argentina Syndrome Progressive Ataxia Weakness Disorder Treatment Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, 2018-2029
6.7.2 Turkey Syndrome Progressive Ataxia Weakness Disorder Treatment Market Size, 2018-2029
6.7.3 Israel Syndrome Progressive Ataxia Weakness Disorder Treatment Market Size, 2018-2029
6.7.4 Saudi Arabia Syndrome Progressive Ataxia Weakness Disorder Treatment Market Size, 2018-2029
6.7.5 UAE Syndrome Progressive Ataxia Weakness Disorder Treatment Market Size, 2018-2029
7 Syndrome Progressive Ataxia Weakness Disorder Treatment Companies Profiles
7.1 Acorda Therapeutics
7.1.1 Acorda Therapeutics Company Summary
7.1.2 Acorda Therapeutics Business Overview
7.1.3 Acorda Therapeutics Syndrome Progressive Ataxia Weakness Disorder Treatment Major Product Offerings
7.1.4 Acorda Therapeutics Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue in Global Market (2018-2023)
7.1.5 Acorda Therapeutics Key News & Latest Developments
7.2 American Regent
7.2.1 American Regent Company Summary
7.2.2 American Regent Business Overview
7.2.3 American Regent Syndrome Progressive Ataxia Weakness Disorder Treatment Major Product Offerings
7.2.4 American Regent Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue in Global Market (2018-2023)
7.2.5 American Regent Key News & Latest Developments
7.3 Baxter International
7.3.1 Baxter International Company Summary
7.3.2 Baxter International Business Overview
7.3.3 Baxter International Syndrome Progressive Ataxia Weakness Disorder Treatment Major Product Offerings
7.3.4 Baxter International Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue in Global Market (2018-2023)
7.3.5 Baxter International Key News & Latest Developments
7.4 Biogen Idec
7.4.1 Biogen Idec Company Summary
7.4.2 Biogen Idec Business Overview
7.4.3 Biogen Idec Syndrome Progressive Ataxia Weakness Disorder Treatment Major Product Offerings
7.4.4 Biogen Idec Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue in Global Market (2018-2023)
7.4.5 Biogen Idec Key News & Latest Developments
7.5 Bristol-Myers Squibb
7.5.1 Bristol-Myers Squibb Company Summary
7.5.2 Bristol-Myers Squibb Business Overview
7.5.3 Bristol-Myers Squibb Syndrome Progressive Ataxia Weakness Disorder Treatment Major Product Offerings
7.5.4 Bristol-Myers Squibb Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue in Global Market (2018-2023)
7.5.5 Bristol-Myers Squibb Key News & Latest Developments
7.6 Cadila Healthcare
7.6.1 Cadila Healthcare Company Summary
7.6.2 Cadila Healthcare Business Overview
7.6.3 Cadila Healthcare Syndrome Progressive Ataxia Weakness Disorder Treatment Major Product Offerings
7.6.4 Cadila Healthcare Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue in Global Market (2018-2023)
7.6.5 Cadila Healthcare Key News & Latest Developments
7.7 Eli Lilly and Company
7.7.1 Eli Lilly and Company Company Summary
7.7.2 Eli Lilly and Company Business Overview
7.7.3 Eli Lilly and Company Syndrome Progressive Ataxia Weakness Disorder Treatment Major Product Offerings
7.7.4 Eli Lilly and Company Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue in Global Market (2018-2023)
7.7.5 Eli Lilly and Company Key News & Latest Developments
7.8 Glaxosmilthkline
7.8.1 Glaxosmilthkline Company Summary
7.8.2 Glaxosmilthkline Business Overview
7.8.3 Glaxosmilthkline Syndrome Progressive Ataxia Weakness Disorder Treatment Major Product Offerings
7.8.4 Glaxosmilthkline Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue in Global Market (2018-2023)
7.8.5 Glaxosmilthkline Key News & Latest Developments
7.9 Sanofi
7.9.1 Sanofi Company Summary
7.9.2 Sanofi Business Overview
7.9.3 Sanofi Syndrome Progressive Ataxia Weakness Disorder Treatment Major Product Offerings
7.9.4 Sanofi Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue in Global Market (2018-2023)
7.9.5 Sanofi Key News & Latest Developments
7.10 Roche Holding
7.10.1 Roche Holding Company Summary
7.10.2 Roche Holding Business Overview
7.10.3 Roche Holding Syndrome Progressive Ataxia Weakness Disorder Treatment Major Product Offerings
7.10.4 Roche Holding Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue in Global Market (2018-2023)
7.10.5 Roche Holding Key News & Latest Developments
7.11 Pfizer
7.11.1 Pfizer Company Summary
7.11.2 Pfizer Business Overview
7.11.3 Pfizer Syndrome Progressive Ataxia Weakness Disorder Treatment Major Product Offerings
7.11.4 Pfizer Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue in Global Market (2018-2023)
7.11.5 Pfizer Key News & Latest Developments
7.12 Novartis AG
7.12.1 Novartis AG Company Summary
7.12.2 Novartis AG Business Overview
7.12.3 Novartis AG Syndrome Progressive Ataxia Weakness Disorder Treatment Major Product Offerings
7.12.4 Novartis AG Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue in Global Market (2018-2023)
7.12.5 Novartis AG Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 進行性運動失調無力症治療の世界市場見通し2023年-2029年(Syndrome Progressive Ataxia Weakness Disorder Treatment Market, Global Outlook and Forecast 2023-2029)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

進行性運動失調無力症治療の世界市場見通し2023年-2029年

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp